628 results about "Cerebral ischaemia" patented technology

The novel amidino derivatives of the formula (I):wherein all the symbols are as in specification defined;have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and / or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.

A non-invasive method of treating cerebral ischemia, involving the use of non-inhaled, intra-nasally delivered carbon dioxide (CO2), alone or in combination with other gases to augment cerebral perfusion and improve outcome following a stroke is provided. A vasodilator gas is delivered intranasally, alone or in combination with a second gas, for prolonged periods of time without systemic absorption. The second gas may be selected from NO, hydrogen, xenon, anesthetic gases, oxygen, nitrogen, nitrous oxide, carbon monoxide, or air. The treatment selectively increases cerebral perfusion and provides neuroprotection in the treatment of cerebral ischemia.

A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and / or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.

The invention discloses an intelligent cerebral stroke drug carrier for ROS (reactive oxygen species) response and a preparation method of the drug carrier. The carrier is a nano vesicle, hydrophobic boric acid ester is grafted to hydrophilic glucan framework to form amphiphilic block copolymers, the amphiphilic block copolymers serve as carrier materials to prepare the nano vesicle, and the nano vesicle encapsulates neuroprotective agents NR2B9C. The preparation method includes the steps: performing covalent grafting for the boric acid ester and glucan; preparing a nano vesicle carrier by grafting reaction carrier materials in an automatically filling manner; encapsulating the neuroprotective agents NR2B9C in the nano vesicle carrier. The weight ratio of the boric acid ester and the glucan is 10: (5-25), the carrier easily responds degradation of ROS mediation, so that drugs rapidly release at cerebral ischemia lesion positions, and release in non-lesion areas is decreased, so that the neuroprotective agents are more safely and effectively transmitted in intracerebral target areas.

The invention belongs to the technical field of medical early warning, and discloses an early warning system and method for cerebral apoplexy. The early warning system for cerebral apoplexy comprisesan image collection module, a physiological index collection module, a main control module, an image processing module, a risk evaluation module, a warning module, a data storage module and a displaymodule. According to the system and method, through the image processing module, automatic identification and segmentation of a cerebral ischemia zone in a super-acute stage can be achieved, and the segmentation precision of the ischemia zone is improved; data preprocessing, feature selection and feature optimization are conducted through the risk evaluation module, and obtained data features aremore effective; an XGBoost method is adopted for automatically generating the risk probability that a target group of people suffer from cerebral apoplexy, community health screening can be more efficiently and conveniently conducted, and a doctor can be helped to more simply and quickly evaluate the risk that the target group of people suffer from cerebral apoplexy; health screening can be strongly pushed, so that potential users with cerebral apoplexy are more quickly found, and earlier warning is given, so that earlier and more effective treatment is conducted.

The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and / or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.

A Chinese medicine for improving cerebral function and preventing cerebra ischemic or anoxic injury, senile dementia and vascular dementia is prepared from astragalus root, rhodiola root and Chinaroot greenbrier rhizome or their extracts. Its preparing process is also disclosed.

The invention discloses a yang supplementing five returning ketoside drug for preventing and treating cardio-cerebrovascular diseases, which is prepared by extracting active ingredient from raw materials of hoantchy root, angelica, red paeonia, hemlock parsley, earthworm and peach kernel. The obtained drug has total glucosides of the hoantchy root as 30-60%, total glucosides oftotal glucosides of the red paeonia as 5-20%, content of safflower flavone as 5-10%, and the remains as the other ingredients extracted from the traditional Chinese medicine materials. The yang supplementing five returning ketoside drug provided by the invention can be added with accessories or auxiliary components acceptable in pharmacy to form various preparations required by clinic. The preparations are: small injection solution, transfusion, freeze-dried powder, tablet, capsule, oral solution, buccal tablet, granule, medicinal granules, pill, powder, suspension, suppository, drop, dropping pill, sustained release preparation, release controlling agent and targeting preparation. The drug of the invention has clearly controllable efficacious components, fast absorption, definitive curative effect, convenience for taking and is effective for preventing and treating cardio-cerebral ischemia diseases.

The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.